Prostate cancer is a global socio-economic problem. A novel diagnostic approach will help to distinguish between Prostate Cancer and Benign Prostatic Hyperplasia, the most common non-cancer prostatic condition in ageing men with symptoms similar or overlapping with those of prostate cancer. The test can be regularly performed by men using a self-monitoring tool or by a GP using a bench top device. The test will monitor the wellness of the prostate, which is typically affected in cancer patients.
Cambridge Oncometrix healthcare company uses a proprietary set of biomarkers and analytical technology to detect prostate cancer.